Skip to main content
Signal8
Launch Terminal

Prime Medicine, Inc. (PRME)

Prime Medicine, Inc. operates as a biotechnology firm, dedicated to delivering genetic therapies for various diseases by strategically employing advanced gene editing technology. Central to their platform is the "Prime Editor" system, which combines a unique Prime Editor protein—a hybrid composed of a Cas protein and a reverse transcriptase enzyme—with a specialized pegRNA molecule. This pegRNA plays a crucial role by both guiding the Prime Editor to a precise location within the genome and providing the essential template for introducing the desired modification to the target DNA sequence. The company, founded in 2019, maintains its headquarters in Cambridge, Massachusetts.

Sector: Biological Products, (No Diagnostic Substances)

Industry: Biotechnology

Prime Medicine, Inc. logo

Prime Medicine, Inc.

NASDAQ:PRMEHealthcare
-9.92%$4.72
AH$4.70-0.33%vs close
Mkt Cap$856.1M
Float95.66M
O/S181.38M
Vol
$ Vol
RVOL
Inst Own59.2%
SI34.4%
Earnings
Dilution
Prime Medicine, Inc. logoNASDAQ:PRME$4.72-9.92%
Pipeline4 lead-sponsored trials·3 active0 completed

Trials need funding. See this company's dilution risk and cash position.

Clinical Trials
Status
Phase
  • Phase 1/2
    Enrolling by invitation

    A Study of the Safety and Efficacy of Prime Editing (PM359) in Participants With p47phox Autosomal Recessive Chronic Granulomatous Disease (CGD )

    PM359

    Chronic Granulomatous Disease, Granulomatous Disease, Chronic

    Enrollment
    12
    Start
    Oct 2024
    Primary Completion
    Jan 2030est.
    Completion
    Feb 2030est.
    NCT06559176
  • Phase 1/2
    Recruiting

    A Study of the Safety and Efficacy of Prime Editing (PM577) in Participants With Wilson Disease (WD)

    PM577a

    Wilson Disease, Wilson's Disease +1

    Enrollment
    42
    Start
    Sep 2026est.
    Primary Completion
    Nov 2028est.
    Completion
    Dec 2028est.
    NCT07748403
  • Phase 1/2
    Not yet recruiting

    A Study of the Safety and Efficacy of Prime Editing (PM647a) in Participants With Alpha-1 Antitrypsin Deficiency

    PM647a

    Alpha-1 Antitrypsin Deficiency, Alpha-1 Antitrypsin Deficiency-associated Lung Disease +2

    Enrollment
    54
    Start
    Oct 2026est.
    Primary Completion
    Dec 2028est.
    Completion
    Jan 2029est.
    NCT07887347
  • Observational
    Active, not recruiting

    Prescreening Study to Identify Potential Wilson Disease Participants for Gene-Editing Clinical Trial

    -

    Wilson Disease

    Enrollment
    30
    Start
    Dec 2025
    Primary Completion
    Dec 2027est.
    Completion
    Dec 2027est.
    NCT07226622
Search ClinicalTrials.gov for “Prime Medicine”